Hangzhou Diagens Biotechnology Co., Ltd. (HKG:2526)
Hong Kong
· Delayed Price · Currency is HKD
271.00
+1.80 (0.67%)
At close: Apr 29, 2026
HKG:2526 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 |
| Revenue | 164.42 | 70.35 | 52.84 |
| Revenue Growth (YoY) | 133.72% | 33.13% | - |
| Cost of Revenue | 46.34 | 24.29 | 15.35 |
| Gross Profit | 118.09 | 46.06 | 37.5 |
| Selling, General & Admin | 84.74 | 50.57 | 51.84 |
| Research & Development | 104.35 | 25.52 | 28.64 |
| Other Operating Expenses | - | 2.07 | 1.2 |
| Operating Expenses | 196.5 | 78.15 | 81.68 |
| Operating Income | -78.41 | -32.09 | -44.19 |
| Interest Expense | -0.58 | -21.19 | -16.32 |
| Interest & Investment Income | 0.83 | 1.09 | 1.61 |
| Earnings From Equity Investments | 0.03 | -0.1 | -0 |
| Currency Exchange Gain (Loss) | 0.04 | 0.06 | 0.04 |
| Other Non Operating Income (Expenses) | 8.76 | 8.66 | 2.36 |
| EBT Excluding Unusual Items | -69.34 | -43.56 | -56.5 |
| Gain (Loss) on Sale of Investments | - | - | 0.19 |
| Gain (Loss) on Sale of Assets | 2.2 | 0.18 | - |
| Other Unusual Items | - | - | 0.13 |
| Pretax Income | -67.14 | -43.39 | -56.18 |
| Income Tax Expense | 0 | -0.01 | -0.07 |
| Net Income | -67.14 | -43.38 | -56.12 |
| Net Income to Common | -67.14 | -43.38 | -56.12 |
| Shares Outstanding (Basic) | 80 | 79 | 76 |
| Shares Outstanding (Diluted) | 80 | 79 | 76 |
| Shares Change (YoY) | 1.31% | 3.69% | - |
| EPS (Basic) | -0.84 | -0.55 | -0.74 |
| EPS (Diluted) | -0.84 | -0.55 | -0.74 |
| Free Cash Flow | - | -53.98 | -71.61 |
| Free Cash Flow Per Share | - | -0.68 | -0.94 |
| Gross Margin | 71.82% | 65.47% | 70.95% |
| Operating Margin | -47.69% | -45.62% | -83.62% |
| Profit Margin | -40.83% | -61.65% | -106.19% |
| Free Cash Flow Margin | - | -76.72% | -135.52% |
| EBITDA | -69.11 | -21.22 | -39.47 |
| EBITDA Margin | -42.03% | -30.16% | -74.69% |
| D&A For EBITDA | 9.3 | 10.88 | 4.72 |
| EBIT | -78.41 | -32.09 | -44.19 |
| EBIT Margin | -47.69% | -45.62% | -83.62% |
Source: S&P Capital IQ. Standard template.
Financial Sources.